Elypta's mission is to prevent cancer mortality through earlier detection and closer monitoring.

Elypta’s approach is to measure a system of metabolic biomarkers – a profile of metabolites found to reflect an important process in cancer – in both blood and urine. Our learning algorithms then pin down the patterns specific to various forms of cancer using clinical data. Elypta proudly sponsors the clinical trial series AURORAX to investigate applications in the company’s lead indication renal cell carcinoma from surveillance of recurrence to monitoring treatment response.